Alpharma Announces Changes to Executive Leadership Team

BRIDGEWATER, NJ, Jun 19 (MARKET WIRE) --
Alpharma Inc. (NYSE: ALO), a global specialty pharmaceutical company,
announced today changes to its Executive Leadership Team. Ron Warner has
been appointed to the position of Executive Vice President and Chief
Scientific Officer. In this new role, Ron will advise and guide multiple
late-stage development projects, interface with regulatory agencies in
the US and abroad, ensure technology platforms provide distinct and
sustainable competitive advantages and make resource allocation decisions
based upon increasingly complex choices. Additionally, Ron will support
the newly created Science and Technology Committee of the Alpharma Board
of Directors. Ron, who has been with Alpharma since 2002 and has served
as the Pharmaceuticals Division President since 2005, will continue to
serve on the Company's Executive Leadership Team.

R. Scott Shively has been appointed Senior Vice President, Pharmaceutical
Commercial Operations and will join the Alpharma Executive Leadership
Team. In addition to his existing sales and marketing responsibilities,
Scott will assume responsibility for the pharmaceutical supply chain,
alliance management and the Company's operations in Ireland. Prior to
joining Alpharma in 2007, Scott held senior commercial roles with Altana
AG and Endo Pharmaceuticals Holdings Inc., and had a long multi-national
career with Aventis SA, serving in a variety of sales and marketing
leadership positions.

"With the completion of the sale of the Active Pharmaceutical Ingredients
business and the rapid growth of our Pharmaceuticals business, we have
reached a point where the next organizational evolution should take
place," commented Dean Mitchell, President and Chief Executive Officer.
"As we develop our business, the scientific and commercialization issues
we face will become more complex. The restructuring of our Pharmaceutical
Division will effectively align our organization with the expertise and
focus necessary to address these issues and continue to create long-term
shareholder value."

If you would like to receive Alpharma press releases via email please
contact: investorrelations@alpharma.com.

Alpharma press releases are also available at our
website:
http://www.alpharma.com.

Contact:
Jack Howarth
Vice President, Investor Relations
908-566-4153
Jack.howarth@alpharma.com

About Alpharma

Alpharma Inc. (NYSE: ALO) is a global specialty pharmaceutical company
with leadership positions in products for humans and animals. Alpharma is
presently active in more than 80 countries. Alpharma has a growing branded
pharmaceutical franchise in the U.S. pain market with its KADIAN(R)
(morphine sulfate extended-release) Capsules, and the FLECTOR(R) Patch
(diclofenac epolamine topical patch). In addition, Alpharma is also
internationally recognized as a leading provider of pharmaceutical
products for poultry and livestock.

Contact:
Jack Howarth
Vice President, Investor Relations
908-566-4153
Email Contact

Copyright 2008, Market Wire, All rights reserved.

-0-